UBS analyst Andrew Mok raised the firm’s price target on Tenet Healthcare to $104 from $95 and keeps a Buy rating on the shares. Tenet delivered on high expectations, managed contract labor costs well, and is still most likely to outperform numbers in the back-half of the year, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on THC: